{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoJG7ocEIDA","lastupdate":"2024-11-17T00:00:00.000Z","update_date":"2024-11-17T00:00:00.000Z","lastModified":"Feb 20, 2025","active":1,"confidence_score":100,"confidence_score_reason":"markets","urlname":"aeye-health","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$EZYhpCvBJWKBccFsGDO5BXhe2ohyoFW9wA3Hx7gEGUE2UhqGSKBRHa","name":"AEYE Health","oneliner":"AI-based Diagnosis of Retinal Screenings ","registrar":"515933067","website":"https://www.aeyehealth.com/","careerspage":"","founded_month":6,"founded_year":2018,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/aeyehealth","youtube":"https://www.youtube.com/@aeyehealth888","facebook":"","linkedin":"https://www.linkedin.com/company/52141090","instagram":""},"social":["https://www.linkedin.com/company/52141090","https://www.youtube.com/@aeyehealth888","https://twitter.com/aeyehealth"],"flattenedsociallinks":"https://www.linkedin.com/company/52141090|https://www.youtube.com/@aeyehealth888|https://twitter.com/aeyehealth","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"11-50","employees_exact":36,"patent":1,"raised":10000000,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["AI Health"],"about":"AEYE Health is a venture-backed, FDA-approved digital health startup that developed AI algorithms that provide immediate, totally autonomous, point-of-care interpretation of fundus images for various conditions.\nIts products put the power of retinal screenings in the hands of primary care physicians, helping them make sure their patients avoid preventable vision loss.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"bf8e71d3-3c80-4323-891c-d55d3213eba4","city":"Tel Aviv-Yafo","type":null,"address":"HaArba'a Street 28, Tel Aviv-Yafo, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"9bf6823e-46d1-4fa8-a8a5-167b0e66d2d9","city":"New York","address":"200 Park Avenue, New York, NY, 10166-0005","country":"United States","placeid":null}]},"headquarter_address":null,"district":"Center District","news":[{"id":"8rIWhN3AprsOnEC25mZJnoniEQfHp8RrmalqiMK29uYfAlj8FLMeHW","date":"Apr 30, 2024","link":"https://www.prnewswire.com/news-releases/fda-clears-first-fully-autonomous-ai-for-portable-diabetic-retinopathy-screening-302131559.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"FDA Clearance, AI Technology, Diabetic Retinopathy","company":"AEYE Health","layoffs":"N/A","summary":"AEYE Health, a leading company for AI retinal imaging and diagnostics, has received FDA clearance for a fully autonomous AI that diagnoses referable diabetic retinopathy from retinal images obtained by a handheld camera. This technology, combined with a portable handheld device, offers a new and affordable screening solution to address the leading cause of blindness in the working age. The AEYE Diagnostic Screening technology (AEYE-DS) is already FDA-cleared and commercially available with a tabletop imaging device. This new clearance is based on two large-scale prospective phase-III studies.","partners":"Optomed Aurora","customers":"Patients with diabetes","investors":"N/A","confidence":9,"key_topics":["FDA Clearance","AI Technology","Diabetic Retinopathy","Handheld Camera","Screening Solution"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"EsZnFl4VeOxkxqIkpBxN2fxbKayFImQvV8DwbeMJVzivqix82iMvT9","news_summary":"FDA clears first fully autonomous AI for portable diabetic retinopathy screening","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Uk4slA9qB9jfsNZBQhWwehpeFfZxoQTshu61X4Og91EOBTiPnKzqBu","date":"Jul 11, 2023","link":"https://www.prnewswire.com/news-releases/iris-and-aeye-health-announce-partnership-to-provide-ai-screening-to-market-301874034.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Partnership, Artificial Intelligence, Retinal Imaging","company":"Intelligent Retinal Imaging Systems (IRIS), AEYE Health","layoffs":"Not mentioned","summary":"Intelligent Retinal Imaging Systems (IRIS) has announced a partnership with AEYE Health, a leading artificial intelligence company for retinal imaging and diagnostics. Under the agreement, IRIS will license AEYE Diagnostic Screening (AEYE-DS) from AEYE Health, an FDA-cleared AI technology that integrates with the IRIS Solution. This partnership allows IRIS customers to use AEYE-DS for the autonomous detection of diabetic retinopathy and receive an instantaneous result using only one image per eye.","partners":"AEYE Health","customers":"IRIS customers","investors":"Not mentioned","confidence":9,"key_topics":"Partnership, Retinal Imaging, Diabetic Retinopathy, Artificial Intelligence, FDA Clearance","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Partners, Customers","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners, Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JtmRN4QtDZYVJg5tsBbFXBOjZbyQcAzRJUCfmdT6Evcr7ry4lkd9AZ","news_summary":"IRIS and AEYE Health Announce Partnership to Provide AI Screening to Market","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cnA5RuU75gTAVkmBSqKZ9nZ8yogtAgrSGt2ETST0xMQC3aRx6dW6F9","date":"Mar 31, 2023","link":"https://www.forbes.com/sites/gilpress/2023/03/31/is-chagpt-fast-becoming-chatmd-introducing-generative-ai-to-healthcare/","source":"www.forbes.com","visible":1,"analysis":{"tags":["AI in healthcare","generative AI","medical education","clinical decision-making"],"company":"OpenAI","layoffs":null,"summary":"OpenAIs ChatGPT, now qualified as ChatMD, has demonstrated a high level of concordance and insights in its explanations for all three parts of the United States Medical Licensing Exam (USMLE). The use of AI in healthcare is growing, with applications ranging from administrative work to diagnosis and treatment. Generative AI is particularly suited for healthcare, as it can process and store doctor-patient conversations and streamline administrative tasks. Synthetic health data, generated for research and analysis while protecting patient privacy, is gaining traction. Startups like Syntegra are using generative AI to create synthetic health data, and companies like EPIC and Nuance Communications are incorporating AI models into their healthcare systems. The promise of AI in healthcare has attracted interest and investments, but there are dissenting voices expressing skepticism about its accuracy and potential cost. Overall, the article highlights the potential and challenges of AI in healthcare.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["AI in healthcare","generative AI","medical education","patient privacy","AI skepticism"],"date_of_event":"December 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UuBCA3rsWB5sQfPcBatSsLprTGtaL3RuMSXAK7BMURmCfYebOU3taa","news_summary":"Is ChatGPT Fast Becoming ChatMD? Introducing Generative AI To Healthcare","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Kl82TgxvSDd3KPjYh034H6n1etxjTScKafLC6JX0bfotKApGjsXAqq","date":"Feb 9, 2023","link":"https://www.umassmed.edu/news/news-archives/2023/02/umass-chan-aeye-health-researching-use-of-ai-based-retinal-camera-screenings-in-primary-care-practice/","source":"www.umassmed.edu","visible":1,"analysis":{"tags":"healthcare, AI","company":"UMass Chan Medical School","layoffs":null,"summary":"UMass Chan Medical School is collaborating with AEYE Health on a pilot study to test a handheld, AI-assisted retinal camera for screening diabetic retinopathy in a primary care setting. The technology, developed by AEYE Health, received FDA clearance. The study aims to increase the number of patients screened by allowing primary care practices to use the AI camera. UMass Chan and AEYE Health received an $800,000 grant for the study from the Israeli-U.S. Binational Industrial Research and Development Foundation.","partners":"AEYE Health","customers":null,"investors":"Israeli-U.S. Binational Industrial Research and Development Foundation","confidence":9,"key_topics":["AI-assisted retinal camera","diabetic retinopathy","pilot study","primary care setting","screening"],"date_of_event":"April","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xKV121xqDqxU15rn0XnS6l0irge26WmOKwtijwwFRmpTJ6hxQiaNS3","news_summary":"UMass Chan, AEYE Health researching use of AI-based retinal camera screenings in primary care practice","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"QsWj0qCsKF0uOXEWUJ9SQXtPcFv1B7E8fDSmTFOKn1gpx9QSrLhbUp","date":"Jan 24, 2023","link":"https://www.prnewswire.com/news-releases/aeye-health-announces-best-in-class-results-proving-ai-software-is-capable-of-predicting-the-future-development-of-diabetic-retinopathy-in-patients-before-diagnosable-symptoms-manifest-301729396.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"AI, disease prediction","company":"AEYE Health","layoffs":null,"summary":"AEYE Health, a leading AI company for retinal-based diagnostics, has published a paper describing the development of a deep learning algorithm that can accurately predict the future development of diabetic retinopathy. The algorithm uses fundus imagery of otherwise healthy eyes and has high efficacy. The study highlights the clinical benefits of disease prediction, allowing for more closely monitored high-risk patients and potential preventative treatment. The publication comes two months after AEYEs FDA clearance for diabetic retinopathy screening, showcasing their best-in-class technology. AEYEs solution is currently being deployed in primary care clinics to address care gaps. The article does not mention any specific partners, customers, or financial details.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["AI","disease prediction","diabetic retinopathy","screening","fundus imagery"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"27QI9HjGlkba4Tr1zXQ9XfWS3HNBUAj8pddSpdFAoIdzUwop9RDNPw","news_summary":"AEYE Health announces best-in-class results, proving AI software is capable of predicting the future development of diabetic retinopathy in patients before diagnosable symptoms manifest","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2abJHus28HNBmRbpTQWre7hJNFONdMDS6YbaursO57jfdmvVVAFTI3","date":"Dec 15, 2022","link":"https://www.medscape.com/viewarticle/985678","source":"www.medscape.com","visible":1,"analysis":{"tags":["AI","diabetic retinopathy","healthcare","screening","primary care"],"company":"OSF HealthCare","layoffs":null,"summary":"OSF HealthCare, a network of medical facilities, has piloted an AI system to diagnose diabetic retinopathy and plans to expand the technology to 34 locations. The FDA has approved a new AI system from AEYE Health for the same purpose. Physicians have mixed responses to AI screening, with concerns about unrecognized biases. The American Medical Association has released a new CPT code to allow clinicians to bill for these services. AI screening can help underserved areas where eye care providers are not available. OSF HealthCare has obtained a $1 million grant from Regeneron to expand the use of AI-based screening. The company Digital Diagnostics, which owns the IDx-DR platform used by OSF, has received investments from OSF Ventures and KKR. AI has the potential to analyze retinal images for other conditions and may be used in interpreting ECGs.","partners":null,"customers":null,"investors":["Regeneron","OSF Ventures"],"confidence":8,"key_topics":["AI in healthcare","diabetic retinopathy screening","primary care clinics","AI algorithms","accessibility to technology"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WZFWnpEVAPQUYNuUq9NnhgPx5M8vmcpvwAP9qvR1LC21gk8vL44sqk","news_summary":"AI Takes Root in Primary Care. First Stop: Diabetic Retinopathy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"rs7ZvutOf28wHN4GNgiit0S6wSpkfAepcnnrzkRjPTTti1eSR0iNB6","date":"Nov 15, 2022","link":"https://www.prnewswire.com/news-releases/aeye-health-receives-fda-clearance-for-ai-based-autonomous-screening-for-referable-diabetic-retinopathy-301678515.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"AI-based retinal imaging, diagnostic screening system, diabetic retinopathy","company":"AEYE Health","layoffs":null,"summary":"AEYE Health has received a 510(k) clearance from the U.S. Food & Drug Administration (FDA) to market its diagnostic screening system for diabetic retinopathy. The companys technology offers best-in-class clinical efficacy with 93% sensitivity and 91.4% specificity, and it requires only a single image per eye, shortening the screening process to one minute. This approval revolutionizes diagnostic screening for diabetic retinopathy and has significant growth-positive impact on AEYE Health.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["AI-based retinal imaging","diagnostic screening system","diabetic retinopathy","FDA approval","clinical efficacy"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RctWHO2Gx2xjs8JEJX7IJva3S0e0CvEprxr3vTRPKvOJTwJz36KfaP","news_summary":"AEYE Health receives FDA clearance for AI-based autonomous screening for referable diabetic retinopathy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cf0078b2-e3b6-4df0-accf-5e6f0f0a727f","date":"Jul 26, 2022","link":"https://www.calcalist.co.il/calcalistech/article/bk8iuea3q","source":"www.calcalist.co.il","visible":1,"analysis":{"tags":"medical technology","company":"Aeye Health","layoffs":null,"summary":"Israeli company Aeye Health has developed a technology that allows for early detection of various diseases, including those that cause blindness, through retinal scanning. The company, founded in 2018, uses artificial intelligence and a simple testing system to diagnose diseases that previously required time-consuming and complex tests. The technology has the potential to detect dozens of eye-related diseases, as well as non-eye-related conditions such as high blood pressure, heart problems, dementia, kidney problems, and various types of cancer. Aeye Health is awaiting FDA approval and already provides services to thousands of patients in the United States. The company has raised $10 million in funding.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Aeye Health","early disease detection","artificial intelligence","retinal scanning","prevention of blindness"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2e1T55MCPktyYL8tA6pPMfFwNo7LkPfsX2Dj6b55QNUeH5t2BQUuxQ","news_summary":"מונעת עיוורון: Aeye Health פיתחה תוכנת AI לאבחון סוכרת דרך הרשתית  כלכליסט","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"18a48d47-a2b4-4e8c-8eba-ec1a3f36dc66","date":"Feb 7, 2022","link":"https://www.prnewswire.com/news-releases/aeye-health-reports-pivotal-clinical-trial-results-of-its-ai-algorithm-for-the-autonomous-screening-and-detection-of-more-than-mild-diabetic-retinopathy-301476299.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["diabetic retinopathy","AI-based systems","autonomous detection","FDA-clinical trial"],"company":"AEYE Health","layoffs":null,"summary":"AEYE Health, an ophthalmic technology company, has reported the results from its FDA-clinical trial for the autonomous detection of more-than-mild diabetic retinopathy. The study evaluated the accuracy of AI software in detecting diabetic retinopathy using a single image per eye. The results showed high sensitivity and specificity for both desktop and handheld retinal cameras. AEYE Health aims to make diagnostic screening for diabetic retinopathy accessible and affordable. The company is seeking FDA clearance for its autonomous screening solution and is also working on diagnosing glaucoma using digital fundus images.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["diabetic retinopathy","AI-based systems","FDA-clinical trial","screening","prevention"],"date_of_event":"2022-02-07","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"p3PV1ankZm7CIy2zaVrLO96x0R5404xQ8KmrumzaDf73kPAFOth5C0","news_summary":"AEYE Health Reports Pivotal Clinical Trial Results of its AI Algorithm for the Autonomous Screening and Detection of More-Than-Mild Diabetic Retinopathy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"931d9e04-6bdb-4e59-bd54-7a3b50157a80","date":"Mar 30, 2021","link":"https://www.prnewswire.com/news-releases/umass-medical-school-and-aeye-health-leverage-ai-to-help-family-doctors-screen-and-refer-patients-with-eye-conditions-to-specialists-301258509.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"AI, healthcare","company":"AEYE Health","layoffs":null,"summary":"AEYE Health and UMass Medical School are collaborating to develop a system that enables family doctors to screen patients for retinal conditions using AI. The system will be incorporated into UMasss patient treatment protocols to automatically diagnose diseases from digital fundus images. The partnership is supported by a BIRD Foundation grant. The goal is to improve screening performance and prevent vision loss by detecting and treating eye diseases early.","partners":"UMass Medical School, UMass Memorial Health Care","customers":null,"investors":null,"confidence":9,"key_topics":["AI","retinal screening","UMass Medical School","UMass Memorial Health Care","BIRD Foundation"],"date_of_event":"March 30, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"poYM9ZDUcSziqwfDxqqa0U0PUpyf8A4HzD5GrNFDlYTgPT5OvY0flz","news_summary":"UMass Medical School and AEYE Health leverage AI to help family doctors screen and refer patients with eye conditions to specialists","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3ac42534-02ff-4973-bb0a-fc3242165ebd","date":"Mar 21, 2021","link":"https://en.globes.co.il/en/article-biolight-invests-in-1m-in-aeye-health-1001364773","source":"en.globes.co.il","visible":1,"analysis":{"tags":"investment","company":"BioLight Life Sciences","layoffs":null,"summary":"BioLight Life Sciences has completed an investment of $1 million in AEYE Health, a developer of AI-based ophthalmic diagnostics technology. BioLight has an option to invest a further $1.5 million in AEYE Health, contingent on progress in its trial and FDA approval. The investment reflects BioLights expansion in the field of digital health and preference for companies close to the revenue stage.","partners":null,"customers":null,"investors":["Naska Medical","Club 100 plus","Prof. Sean Ianchulev"],"confidence":9,"key_topics":["BioLight Life Sciences","AEYE Health","investment","AI-based ophthalmic diagnostics technology","FDA approval"],"date_of_event":"March 21, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$1 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"izdBpF03oW0y9BmcJqvqglVssAryjv8sOSLpW7M4myIYVTsAwsRnDX","news_summary":"BioLight invests in $1m in AEYE Health","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e300bd6f-d087-426f-ae94-0f10fa026cc4","date":"Dec 7, 2020","link":"https://www.aop.org.uk/ot/science-and-vision/technology/2020/12/07/ai-screening-for-diabetic-retinopathy","source":"www.aop.org.uk","visible":1,"analysis":{"tags":"AI, retinal screening","company":"AEYE Health","layoffs":null,"summary":"AEYE Health has partnered with Optomed to produce a handheld fundus camera integrated with AI for retinal screening. The device aims to make screening for more-than-mild diabetic retinopathy more accessible. The device provides instant reports and analysis securely on the Cloud. It is designed for clinics or practices new to diabetic retinopathy screening and can be used in primary care settings. AEYE Health plans to add additional capabilities to the device in the future. The company aims to cover screening for diabetic patients and enable early detection of retinal diseases or diabetic retinopathy changes.","partners":"Optomed","customers":null,"investors":null,"confidence":8,"key_topics":["AI","retinal screening","handheld fundus camera","diabetic retinopathy","screening accessibility"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"D0Yq447PYmU4pV9Hr8vwfyKjIVr6wOuE9WO4XXQpRNO6bYsgxWZtKC","news_summary":"AI screening for diabetic retinopathy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0cb73b6f-1dca-4ea3-9484-9144a273bada","date":"Nov 16, 2020","link":"https://www.hitechies.com/zack-dvey-aharon-ceo-co-founder-of-aeye-health/","source":"www.hitechies.com","visible":1,"analysis":{"tags":"healthcare, AI-based diagnostic screening","company":"AEYE Health","layoffs":null,"summary":"The article features an interview with Zack Dvey Aaron, the CEO and Co-Founder of AEYE Health, a digital health company focused on automated, AI-based diagnostic screening solutions for retinal imaging. The company collaborates with advanced academic medical centers in the United States and its solution is already being used in primary care clinics. The interview discusses topics such as the future of healthcare, regulatory challenges in healthcare, telehealth, COVID-19 challenges, and entrepreneurship. The article highlights Zacks background and how he became interested in using machine learning to advance healthcare. The interview also mentions Zacks collaboration with Danny Margalit, the former founder of one of Israels largest tech companies, in establishing AEYE Health.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Future of Healthcare","Regulatory Challenges in Health Care","Tele Health","Covid 19 Challenges","Entrepreneurship and the journey"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"qHSQc4pyyvjY1W78aD2PH6qNQkP8lcnF7JfEON1QJcKTKwPxgFXPi4","news_summary":"Zack Dvey-Aharon, CEO and Co-Founder of AEYE Health Talks to Pramod Dhakal","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"37780df5-a655-42f7-a406-e9850c5e8eea","date":"Nov 10, 2020","link":"https://www.wired.com/story/us-government-pay-doctors-use-ai-algorithms/","source":"www.wired.com","visible":1,"analysis":{"tags":["AI in healthcare"],"company":"Viz.ai","layoffs":null,"summary":"The US Centers for Medicare & Medicaid Services (CMS) has announced that it will pay for the use of two AI systems developed by Viz.ai and Digital Diagnostics. One AI system can diagnose a complication of diabetes that causes blindness, while the other alerts a specialist when a brain scan suggests a patient has suffered a stroke. The decisions by CMS to pay for these AI systems could drive wider use of AI in healthcare. The products are already cleared by the FDA and are in use by some providers. The willingness of the US government to pay for AI tools could be good news for other companies working on medical AI products.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["AI breakthroughs","Medical AI","US government","Medicare and Medicaid","AI in healthcare"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"BEPjsayLDf9VIjL5UsTjE3PE383HKc7k5lEF7dfKOSg8Aj9eY1ty0k","news_summary":"The US Government Will Pay Doctors to Use These AI Algorithms","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"30999899-4541-4458-967a-626fb156a7d1","date":"Oct 15, 2020","link":"https://www.israel21c.org/diagnosing-retinal-disease-with-artificial-intelligence/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"Healthcare, AI, Eye Care","company":"AEYE Health","layoffs":"Not specified","summary":"Israeli start-up AEYE Health has developed an AI software that can quickly diagnose retinal diseases such as glaucoma and diabetic retinopathy. The software uses AI and neural networks to compare patients eye scans with AEYE Healths online database of healthy and diseased eye images. The company is currently conducting clinical trials in the US and hopes to receive FDA certification by the end of 2020. AEYE Health has also announced a new partnership with UMass Health Care in Massachusetts, backed by a BIRD Foundation grant just shy of $1 million.","partners":"UMass Health Care","customers":"Not specified","investors":"Not specified","confidence":9,"key_topics":["Retinal Disease","AI Diagnosis","Clinical Trials","Partnership","Investment"],"date_of_event":"Not specified","valuation_amount":"Not specified","impact_on_company":"growth-positive","investment_amount":"$3 million","structured_issues":["Investment","Partners"],"acquisition_amount":"Not specified","structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1Igt3HjFRiucKAL5cJCwvZ6e6zK5o6TvlditwcFAxuQrOXwQUjgreW","news_summary":"Diagnosing retinal disease with artificial intelligence","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5f599c2d-c505-4878-bb98-e255d0f24202","date":"Sep 21, 2020","link":"https://www.geektime.com/aeye-health-partners-with-optomed/","source":"www.geektime.com","visible":1,"analysis":{"tags":"Partnership, MedTech, AI diagnostics, Retinal scanning","company":"AEYE Health","layoffs":"Not mentioned","summary":"Israeli MedTech startup AEYE Health has entered a strategic partnership with Finnish digital health company Optomed. AEYE Health has developed an AI-powered diagnostic retinal scan, which will be combined with Optomed’s fundus camera capabilities for a clinical trial aimed at securing FDA approval for autonomous AI retinal scanning. The partnership aims to democratize diagnostic eye screenings and ensure timely treatment for patients. Once the clinical trials are successfully completed, the Aurora AEYE retinal scanner will include Optomeds handheld fundus camera Aurora and AEYE Healths AI-based retinal screening system.","partners":"Optomed","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Strategic partnership, AI diagnostics, Retinal scanning, FDA approval, Clinical trial","date_of_event":"21 Sep 2020","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Partners","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"7mkQitqitubYcarLCtzB8wYUhNrsgH7sxU7X8GBRd8ncilKjSQWYZn","news_summary":"Israeli startup AEYE Health & Optomed join forces, aiming for FDA OK on AI diagnostics tool","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"685b532d-77b6-4eb3-b52c-6ee230b19270","date":"Sep 1, 2020","link":"https://www.prnewswire.com/news-releases/aeye-health-develops-advanced-ai-based-retinal-screening-with-instant-results-301122172.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["AI-based retinal screening system","retinal diseases","machine learning","artificial intelligence","partnerships"],"company":"AEYE Health","layoffs":null,"summary":"AEYE Health has developed an AI-based retinal screening system that provides analysis and diagnostic results within 60 seconds. The company aims to address the high risk of retinal diseases that lead to blindness by offering instant and accurate screening and analysis of the retina. The system can be used outside the ophthalmologists office, making it more accessible. AEYE Health has partnered with UMass and Roche Pharmaceuticals to develop new retinal screening solutions for hospitals, pharmacies, and clinics. The article highlights the companys focus on early detection, affordability, and usability to prevent blindness and save lives.","partners":["UMass","Roche Pharmaceuticals"],"customers":null,"investors":null,"confidence":9,"key_topics":["AI-based retinal screening system","retinal diseases","machine learning","artificial intelligence","partnerships"],"date_of_event":"September 1, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"7xxchSnjrEAQefHgCge22JzeYYG5UVH63Q1gatbgqNKVhdxDBVd8mw","news_summary":"AEYE Health develops advanced AI-based retinal screening with instant results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a02f0e56-b136-4fc3-b192-69101ea1d560","date":"Aug 13, 2020","link":"https://nocamels.com/2020/08/aeye-health-eye-scan-diagnose-avoidable-blindness/","source":"nocamels.com","visible":1,"analysis":{"tags":"retinal screening","company":"AEYE Health","layoffs":null,"summary":"AEYE Health, a digital health company, is developing a system for quick retinal scans that can detect various medical conditions. The company aims to make retinal screening more accessible and affordable by integrating its AI software solution into existing and new eye-scanning devices. AEYE Healths algorithms are based on artificial intelligence, machine learning, and computer vision technologies. The company hopes to secure FDA approval for its diagnostics platform by the end of the year. AEYE Health is collaborating with UMass Memorial Health Care to develop a software solution for hospitals. The companys goal is to enable easy access to retinal scans and promote regular testing for early disease detection and prevention.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["retinal screening","AI technology","medical conditions","accessibility","prevention"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4Osq3TgcgxcCUN8sQOgjKhLwj9leqECrkYLL21rqbYKi052nQgCflt","news_summary":"AEYE Health's Simple Eye Scan To Diagnose, Prevent Avoidable Blindness","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b93c92c9-8e0c-4dbd-b438-d305719167ee","date":"Jul 15, 2020","link":"https://www.masslive.com/worcester/2020/07/umass-memorial-health-care-and-israeli-company-to-collaborate-on-new-solution-to-prevent-avoidable-blindness.html","source":"www.masslive.com","visible":1,"analysis":{"tags":"healthcare, partnership","company":"UMass Memorial Health Care","layoffs":null,"summary":"UMass Memorial Health Care is partnering with AEYE Health, an Israeli health company, to develop a new paradigm to prevent avoidable blindness. The partnership is funded by the Binational Industrial Research and Development Foundation with $8 million. The goal is to use advanced machine learning techniques to provide an immediate automatic diagnosis from fundus images, which can help detect various medical conditions and prevent blindness. The technology aims to empower clinicians with real-time information for timelier and better-informed diagnoses. This partnership is expected to have a positive impact on UMass Memorial Health Cares growth.","partners":["AEYE Health"],"customers":null,"investors":null,"confidence":9,"key_topics":["prevent avoidable blindness","machine learning","diagnosis","retinal diseases","patient eye care"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"tJ8Qr90hXC8RsF63Z00onqTsDzJIkdjGc98nXnFH57a4r1aOozbmpD","news_summary":"UMass Memorial, Israeli company to collaborate on new solution to prevent avoidable blindness","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"18a461f2-0c3d-4663-a069-3d3588b2f61f","date":"Jun 8, 2020","link":"https://www.geektime.com/great-optics-israeli-innovation-scans-your-eyes-to-revolutionize-disease-diagnostics/","source":"www.geektime.com","visible":1,"analysis":{"tags":"Healthcare, Diagnostics","company":"AEYE Health","layoffs":null,"summary":"Israeli startup AEYE Health has raised $3 million in funding to develop its algorithm that uses computer vision and machine learning to diagnose various diseases by scanning the retina in the eye. The company aims to provide a more efficient and accessible way of diagnosing diseases, such as blindness, Alzheimers, and cancer, without the need for expensive machinery. AEYE Healths software solution can be integrated with existing eye-scanner cameras, making it accessible to family doctors and medical care centers. The company is currently in the final stages of clinical testing in the U.S. and is seeking FDA approval for its technology.","partners":null,"customers":null,"investors":["Falcon","R-Cubed","Club 100","Angel investors"],"confidence":9,"key_topics":["AEYE Health","diagnostics","retina scans","AI software","FDA approval"],"date_of_event":"8 Jun 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$3 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2jJmnG2OVkdZY45nEz3i9utuz5jL3aFI8rIw2c4Lgs6ELAtriTQcA2","news_summary":"Great optics: Israeli innovation scans your eyes to revolutionize disease diagnostics","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":20,"techcommunityinvolvement":null,"mediagallery":[{"id":"Adn9WnhFeHFsNovcjZPwfkdflViqt6q50Q4fT9ktRCzszCTyjuHm05","timestamp":"2023-09-11 18:36:15.000000","resources_type":2,"resources_title":"","resources_file_name":"6QVlkAU4VNM","alt":"","imageurl":"https://img.youtube.com/vi/6QVlkAU4VNM/0.jpg","url":"http://youtu.be/6QVlkAU4VNM"}],"tags":["deep-learning","decision-making","artificial-intelligence","data-analytics","big-data","predictive-analytics","diagnostics","monitoring","machine-learning","non-invasive","digital-healthcare","ophthalmology","patent-pending","early-detection","diabetes","eye-diseases","glaucoma","computer-vision","alzheimers-disease","home-care"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":[],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":6,"lastfunding":"$5.7M","totalrounds":3,"fundingstage":"Seed","totalfunding":"$10M","publicinvestors":6,"lastpublicfunding":5700000,"totalpublicrounds":3,"totalpublicfunding":10000000},"team":[{"name":"Zack Dvey-Aharon","email":"zack@aeyehealth.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNG2m8oKDA","bounced":false,"claimed":0,"founder":1,"urlname":"zack-dvey-aharon","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgjMLW3AgM","position":"Founder & CEO","last_name":"Dvey-Aharon","claimtoken":"QmExtu2HaBTvIn5U9BBWN2v1s8lJigUYJrZtiONxEO51eRLGSS8RLl","first_name":"Zack","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/zackda","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-09-11 18:37:14.000000","initials":"ZD","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Danny Margalit","email":"danny@aeyehealth.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNHWwO8LDA","bounced":false,"claimed":0,"founder":1,"urlname":"danny-margalit","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg0czNuwgM","position":"Founder & COO","last_name":"Margalit","claimtoken":"0MTzpy8jeePmTthskf9bON4RmGJmVkvZHFPnH14luTOKWwanDxhzIg","first_name":"Danny","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/danny-margalit-0a471b60/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-09-11 18:37:18.000000","initials":"DM","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Amit Wohl","email":"amit@aeyehealth.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4P7Nj5QKDA","bounced":false,"claimed":0,"founder":0,"urlname":"amit-wohl","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgwcDKjwoM","position":"VP Product & Marketing","last_name":"Wohl","claimtoken":"9181718b958a23b9e5e6a74e5692338ed05801e491950f4b39b35a67e9e5225c","first_name":"Amit","picturekey":"$QdwM0ElUbIC33Y4FEDCzmeAPjzKdoBxl7zoAw2iLJsdGEKY7NZKhJO","claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/amit-wohl-882b6/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-07-27 13:48:39.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$QdwM0ElUbIC33Y4FEDCzmeAPjzKdoBxl7zoAw2iLJsdGEKY7NZKhJO","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Gal Jacob Cohen","email":"gal@aeyehealth.com","phone":"","gender":"Male","userid":"zTcepnOgUF1zAPAhLDpQCxC2c9PsYT4S6zYEYIY61OfmrVz2lcRlZn","bounced":false,"claimed":null,"founder":0,"urlname":"gal-jacob-cohen","visible":1,"memberid":"aWvXA1qiigHTPAKK9LtoeX3iaQ4hfii4a4ChAvAmn1EjsayCtPY8kC","position":"Acting Medical Director","last_name":"Cohen","claimtoken":"MzBQhDTKRwaFflPp3RPbk6KgVPBkibF4EI3W4Exgo46zYG39waxWo7","first_name":"Gal Jacob","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/gal-jacob-cohen-md/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2023-09-12 11:24:22.000000","initials":"GC","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Nathan Lipson","email":"nathan@aeyehealth.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4N6-hJAKDA","bounced":false,"claimed":1,"founder":0,"urlname":"nathan-lipson","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICQ1IWgiAkM","position":"Marketing Manager","last_name":"Lipson","claimtoken":"fd2db91c87cbd4c63e5ca91c02c82e71180a65771d50e09f24c19c0f2c82a7b5","first_name":"Nathan","picturekey":"$YX3UOn3legm5a0koQgrkf5J2smwb2JxC3OyWl4bC1M7ENZk3O0Mh48","claimeddate":"2022-03-30","linkedinurl":"https://www.linkedin.com/in/lipson/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-03-30 09:46:29.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$YX3UOn3legm5a0koQgrkf5J2smwb2JxC3OyWl4bC1M7ENZk3O0Mh48","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwPi8kYoKDA","fullname":"Ayelet Beazley"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-10-01T00:00:00.000Z","crunchbaseid":"aeye-health","lastupdator":"Matan Eblagon","lastupdator_email":"matane@sncentral.org","creator":"Yotam Maman","creator_email":"yotamm1988@gmail.com","createdate":"2018-03-11T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Ayelet Beazley","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCM-Z6sCQw","date":"Jan 2022","amount":"$5.7M","source":"Added by Nathan Lipson + our crowd: https://www.ourcrowd.com/companies/aeye-health","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"HseeUBQoTitgNrfbAL5vR66F1Xutqumsnp29E17q8x2RU5QDm185o4","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"OurCrowd","type":"Investor","amount":1255350,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"hO2ggJGk1OTYPCvbSPfMGFhtnNPaDdeX5huo809g5kwBOHgCqbgF2B","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":5700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"iPcYgi5IpeSe04pkiv1yezVJquiRyExFjAlE56ray0SV7eIaEwa9Rx","date":"Mar 2021","amount":"$4.3M","source":"https://en.globes.co.il/en/article-biolight-invests-in-1m-in-aeye-health-1001364773 + chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://bio-light.co.il/wp-content/uploads/2022/05/BioLight_AeyeHealth_FundRaising_English-KG.pdf","eventtype":"FundingRoundEvent","investment":[{"name":"BIOLIGHT Life Sciences","type":"Investor","amount":1000000,"hidden":false,"country":"Israel","fullurl":"/investor_page/biolight-life-sciences","logokey":"$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","tagline":null,"urlname":"/investor_page/biolight-life-sciences","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OeL444IDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"CtIgv6DybUnQ4EYTmH3HxSiVWYhXXEG3U7Eg7CTERDHBXrUb0dAvk7","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","leadcaption":"","followupcaption":""},{"name":"Sean Ianchulev","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/sean-ianchulev","logokey":"$G4hEtCATvhWCpafglVZVVDDEBuy1U5DzdT5a4hoL6p7nV4G8S5x4HO.jpeg","tagline":null,"urlname":"/investor_page/sean-ianchulev","isisraeli":0,"investorid":"WmRuxEXNhf5OL9ITFQKQKAlwsV5r1CLmE9Sxi7idgnd1J2k27ajVrg","fundingtype":"Angel","leadpartner":null,"investmentid":"JKOEVmvFk7C1JL5m4BhG1sUrIU1OPuLbkjm7xRz8StbACbcz9WqEtg","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$G4hEtCATvhWCpafglVZVVDDEBuy1U5DzdT5a4hoL6p7nV4G8S5x4HO.jpeg","leadcaption":"","followupcaption":""},{"name":"Club 100 Plus","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/club-100-plus","logokey":"$9KzK5hOWpM8gfEJtmPGC54W8YEkJIGaxbakzasODfvy01Mm8jNknA8.jpeg","tagline":"","urlname":"/investor_page/club-100-plus","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODk7rvICww","fundingtype":"Angel Group","leadpartner":null,"investmentid":"NdoiODeyjFoMHeF4Oxw42cmYDplbQziSNDSNlpF3goVGVcufle12XE","fundingsubtype":"Angel Group","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$9KzK5hOWpM8gfEJtmPGC54W8YEkJIGaxbakzasODfvy01Mm8jNknA8.jpeg","leadcaption":"","followupcaption":""},{"name":"Naska Medical","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/naska-medical","logokey":null,"tagline":"","urlname":"/investor_page/naska-medical","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCHjuqTCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"mu5YNvgxBkW49zBXvZK6gSDv3PPdaVwIrJXaUcw63DCSJyfrNLCQec","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":4300000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOC-sZuQCww","hub":"FIBA","date":"Jan 2020","batch":"3","amount":"Undisclosed","hub_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Pzqk9sIDA","source":"From Izik Itzhakov","enddate":"Feb 2020","hub_type":"Accelerator","eventtype":"GraduationEvent","hub_hidden":true,"investment":[],"hub_fullurl":"/program_page/fiba-io","hub_logokey":"$N2YzX7FjOeFAmVmJCnPEY4znsBBVFpXQN3WVfl4ffAyOXYXBpvBhzS","hub_urlname":"/program_page/fiba-io","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"style":"","hiddenCompanyTooltip":"","hub_logourl":"https://storage.googleapis.com/clean-finder-353810/$N2YzX7FjOeFAmVmJCnPEY4znsBBVFpXQN3WVfl4ffAyOXYXBpvBhzS","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCcyLq9CAw","date":"Nov 2018","amount":"Undisclosed","source":"Added by Nathan Lipson","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Pre-Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"6/2018","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"AEYE Health","logourl":"https://storage.googleapis.com/clean-finder-353810/$EZYhpCvBJWKBccFsGDO5BXhe2ohyoFW9wA3Hx7gEGUE2UhqGSKBRHa","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$EZYhpCvBJWKBccFsGDO5BXhe2ohyoFW9wA3Hx7gEGUE2UhqGSKBRHa","seoabout":"AEYE Health is a venture-backed, FDA-approved digital health startup that developed AI algorithms that provide immediate, totally autonomous, point-of-care...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":5,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Digital Medical Diagnostics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":2,"name":"Deep Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","classificationName":"coretechnology"},{"depth":2,"name":"Machine Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","classificationName":"coretechnology"},{"depth":2,"name":"Computer Vision","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA>Deep Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA>Digital Medical Diagnostics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA>Machine Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA>Computer Vision#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA/Digital Medical Diagnostics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA|2:>TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA/Deep Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA|2:>TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA/Machine Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA|2:>TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA/Computer Vision#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Digital Healthcare","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare","children":[{"title":"Digital Medical Diagnostics","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare>Digital Medical Diagnostics"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"},{"title":"Providers","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]},{"title":"Life Sciences","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Artificial Intelligence","key":"0-0","path":"TechnologyClassificationModel>Artificial Intelligence","children":[{"title":"Deep Learning","key":"0-0-0","path":"TechnologyClassificationModel>Artificial Intelligence>Deep Learning"},{"title":"Machine Learning","key":"0-0-1","path":"TechnologyClassificationModel>Artificial Intelligence>Machine Learning"},{"title":"Computer Vision","key":"0-0-2","path":"TechnologyClassificationModel>Artificial Intelligence>Computer Vision"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Digital Medical Diagnostics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":2,"name":"Deep Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","classificationName":"coretechnology"},{"depth":2,"name":"Machine Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","classificationName":"coretechnology"},{"depth":2,"name":"Computer Vision","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Digital Healthcare","Digital Medical Diagnostics"],"coreTechnology":["Artificial Intelligence","Deep Learning","Machine Learning","Computer Vision"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Patients","Providers","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCM-Z6sCQw","date":"Jan 2022","amount":"$5.7M","source":"Added by Nathan Lipson + our crowd: https://www.ourcrowd.com/companies/aeye-health","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"HseeUBQoTitgNrfbAL5vR66F1Xutqumsnp29E17q8x2RU5QDm185o4","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"OurCrowd","type":"Investor","amount":1255350,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"hO2ggJGk1OTYPCvbSPfMGFhtnNPaDdeX5huo809g5kwBOHgCqbgF2B","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":5700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"iPcYgi5IpeSe04pkiv1yezVJquiRyExFjAlE56ray0SV7eIaEwa9Rx","date":"Mar 2021","amount":"$4.3M","source":"https://en.globes.co.il/en/article-biolight-invests-in-1m-in-aeye-health-1001364773 + chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://bio-light.co.il/wp-content/uploads/2022/05/BioLight_AeyeHealth_FundRaising_English-KG.pdf","eventtype":"FundingRoundEvent","investment":[{"name":"BIOLIGHT Life Sciences","type":"Investor","amount":1000000,"hidden":false,"country":"Israel","fullurl":"/investor_page/biolight-life-sciences","logokey":"$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","tagline":null,"urlname":"/investor_page/biolight-life-sciences","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OeL444IDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"CtIgv6DybUnQ4EYTmH3HxSiVWYhXXEG3U7Eg7CTERDHBXrUb0dAvk7","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","leadcaption":"","followupcaption":""},{"name":"Sean Ianchulev","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/sean-ianchulev","logokey":"$G4hEtCATvhWCpafglVZVVDDEBuy1U5DzdT5a4hoL6p7nV4G8S5x4HO.jpeg","tagline":null,"urlname":"/investor_page/sean-ianchulev","isisraeli":0,"investorid":"WmRuxEXNhf5OL9ITFQKQKAlwsV5r1CLmE9Sxi7idgnd1J2k27ajVrg","fundingtype":"Angel","leadpartner":null,"investmentid":"JKOEVmvFk7C1JL5m4BhG1sUrIU1OPuLbkjm7xRz8StbACbcz9WqEtg","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$G4hEtCATvhWCpafglVZVVDDEBuy1U5DzdT5a4hoL6p7nV4G8S5x4HO.jpeg","leadcaption":"","followupcaption":""},{"name":"Club 100 Plus","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/club-100-plus","logokey":"$9KzK5hOWpM8gfEJtmPGC54W8YEkJIGaxbakzasODfvy01Mm8jNknA8.jpeg","tagline":"","urlname":"/investor_page/club-100-plus","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODk7rvICww","fundingtype":"Angel Group","leadpartner":null,"investmentid":"NdoiODeyjFoMHeF4Oxw42cmYDplbQziSNDSNlpF3goVGVcufle12XE","fundingsubtype":"Angel Group","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$9KzK5hOWpM8gfEJtmPGC54W8YEkJIGaxbakzasODfvy01Mm8jNknA8.jpeg","leadcaption":"","followupcaption":""},{"name":"Naska Medical","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/naska-medical","logokey":null,"tagline":"","urlname":"/investor_page/naska-medical","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCHjuqTCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"mu5YNvgxBkW49zBXvZK6gSDv3PPdaVwIrJXaUcw63DCSJyfrNLCQec","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":4300000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCcyLq9CAw","date":"Nov 2018","amount":"Undisclosed","source":"Added by Nathan Lipson","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Pre-Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}